Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Strategies to overcome resistance to EGFR and ALK TKIs

Date

31 Mar 2023

Session

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Topics

Translational Research;  Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Mariana Brandão

Authors

M. Brandão

Author affiliations

  • Brussels/BE

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.